Scientific projects  

Lithium, unlike many other treatments, is not directly supported by the pharmaceutical industry due to its non-patentable status. Consequently, most research on lithium has positioned it as an active comparator, revealing its extraordinary efficacy, particularly as a prophylactic treatment in patients with severe affective disorders.

At IGSLi, our ambition is to establish a significant platform for the dissemination of scientific advancements and to maintain a leading role in fostering international research collaborations. We are dedicated to initiating and supporting collaborative research projects that explore the impact of lithium on treatment outcomes in affective disorders, as well as investigating new treatment avenues, including lithium’s potential neuroprotective effects.

Our research is deeply rooted in a comprehensive array of methodologies, including randomized trials, cohort studies, genetic analyses, and retrospective data studies. We build upon previous research that has explored crucial areas such as the effects of lithium on mortality and morbidity, the genetic predictors of treatment response, and the long-term outcomes of extended lithium therapy. Understanding these dimensions not only enhances our knowledge of lithium’s therapeutic potential but also informs best practices for its use.

Moreover, IGSLi is committed to expanding the use of lithium through the development of evidence-based treatment guidelines. These guidelines will address the effective administration of lithium, including strategies for monitoring its use and managing potential side effects. By providing clear, scientifically-backed recommendations, we aim to support clinicians in optimizing treatment outcomes and ensuring the safe, effective use of lithium in clinical practice